Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Poolbeg Pharma (Uk) Limited currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners across 2 distinct art units. BLUMEL, BENJAMIN P is the busiest examiner, holding 1 pending office action. This busiest examiner pending count of 1 indicates that each of the 2 pending office actions is handled by a different examiner in a different art unit. This lack of examiner concentration means that each pending matter is being handled by a different individual, requiring separate tactical approaches for each case.
The presence of 2 distinct art units indicates that the 2 pending office actions are located in different administrative divisions of the patent office. With 2 distinct examiners and 2 distinct art units, the company must manage two independent prosecution paths. The busiest examiner pending count of 1 confirms that no single examiner has oversight of both pending actions. This distribution requires the legal team to adapt to the preferences of BLUMEL, BENJAMIN P and the other distinct examiner. The 2 pending office actions represent the current total workload for Poolbeg Pharma (Uk) Limited in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 1 | 70.7% | +30.6% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | RAHMANI, NILOOFAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18895929 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | BLUMEL, BENJAMIN P | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18895929 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | BLUMEL, BENJAMIN P | 1671 | §112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18615334 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPoolbeg Pharma (Uk) Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Benjamin P Blumel has the most, with 1 of Poolbeg Pharma (Uk) Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
